MedTrace Logo

Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study

NCT02274727 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2021-11-11

No results posted yet for this study

Summary

The three-year cumulative risk of a recurrent stroke, dependent on aetiology, is up to 25 per cent. At present, preventing recurrence relies on a broad approach to reduce risk factors associated with atherosclerosis, heart disease and metabolic disorders. However, more specific interventions, such as anticoagulation and surgery or stenting, need aetiologic information. BIOSIGNAL aims to determine where the most promising candidate biomarkers can help identify stroke aetiology and also predict overall MACE, including specifically recurrent stroke. In addition, the insights gained into the processes underlying different stroke subtypes may lead to more targeted diagnostic tools.

Conditions

  • Stroke, Acute

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Mira Katan, MD, MS · Name: Mira Katan, MD, Msc

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Germany
  • Greece
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274727 on ClinicalTrials.gov